Everything below concerns GHRH analog. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Prior to entering politics, Jones was a high-pressure liquid chromatographer. She worked at the Washington University School of Medicine and KV Pharmaceutical before becoming a sales director with Mary Kay. In April 2015, Jones was elected to the Ferguson City Council, where she represented the city's first ward. In February 2020, Jones was selected to serve on the United States Environmental Protection Agency Local Government Advisory Committee. In the 2017 municipal election, Jones ran for mayor, receiving 42.77% of the vote. It was the city's first election after the shooting of Michael Brown and subsequent Ferguson unrest. In the June 2, 2020, mayoral election, Jones defeated fellow council member Heather Robinett. Jones succeeded incumbent James Knowles III, a Republican who was unable to seek re-election due to term limits. On June 17, 2020, Jones was sworn in as the first black and female mayor of Ferguson. On April 4 2023, Jones was re-elected as mayor of Ferguson, winning a second term by 21 votes. She is also a pastor in the African Methodist Episcopal Church.
== Bibliography == Audi, G.; Kondev, F. G.; Wang, M.; et al. (2017). "The NUBASE2016 evaluation of nuclear properties". Chinese Physics C. 41 (3) 030001. Bibcode:2017ChPhC..41c0001A. doi:10.1088/1674-1137/41/3/030001. Beiser, A. (2003). Concepts of modern physics (6th ed.). McGraw-Hill. ISBN 978-0-07-244848-1. OCLC 48965418. Hoffman, D. C.; Ghiorso, A.; Seaborg, G. T. (2000). The Transuranium People: The Inside Story. World Scientific. ISBN 978-1-78-326244-1. Kragh, H. (2018). From Transuranic to Superheavy Elements: A Story of Dispute and Creation. Springer. ISBN 978-3-319-75813-8. Zagrebaev, V.; Karpov, A.; Greiner, W. (2013). "Future of superheavy element research: Which nuclei could be synthesized within the next few years?". Journal of Physics: Conference Series. 420 (1) 012001. arXiv:1207.5700. Bibcode:2013JPhCS.420a2001Z. doi:10.1088/1742-6596/420/1/012001. ISSN 1742-6588. S2CID 55434734.
New Sudan (Arabic: السُّودَانُ الْجَدِيدُ, romanized: Āl-Südān(u) āl-Jadīd(u)) is a concept proposed by the Sudan People's Liberation Movement and the Sudan People's Liberation Movement–North, and its constituent paramilitary forces during the Second Sudanese Civil War. The original SPLM Manifesto outlined New Sudan as a proposed united and secular Sudanese state. The vision of 'New Sudan' was developed by John Garang, who advocated the 'New Sudan' as a democratic and pluralistic state. The 1994 National Convention of New Sudan (organized by SPLA/M) redefined 'New Sudan' as a system of governance for the regions under SPLM control. After John Garang's death in 2005 and the independence of South Sudan in 2011, and the resulting decreased ethnic plurality, the New Sudan discourse became a less prominent feature in Sudanese politics.
=== Climate === Climate in this area has mild differences between highs and lows, and there is adequate rainfall year-round. The Köppen Climate Classification subtype for this climate is "Cfb". (Marine West Coast Climate/Oceanic climate).
Sources: en.wikipedia.org
Pleats and creases can be heat-set at higher temperatures More compact molecular structure Better weathering properties; better sunlight resistance Softer "Hand" High melting point (265 °C (509 °F)) Superior colorfastness Excellent abrasion resistance On the other hand, nylon 6 is easy to dye, more readily fades; it has a higher impact resistance, a more rapid moisture absorption, greater elasticity, and elastic recovery.
American black bears were once not considered true or "deep" hibernators, but because of discoveries about the metabolic changes that allow black bears to remain dormant for months without eating, drinking, urinating or defecating, most biologists have redefined mammalian hibernation as "specialized, seasonal reduction in metabolism concurrent with scarce food and cold weather". American black bears are now considered highly efficient hibernators. The physiology of American black bears in the wild is closely related to that of bears in captivity. Understanding the physiology of bears in the wild is vital to the bear's success in captivity. The bears enter their dens in October and November, although in the southernmost areas of their range (i.e. Florida, Mexico, the southeastern United States), only pregnant females and mothers with yearling cubs will enter hibernation. Prior to that time, they can put on up to 14 kg (30 lb) of body fat to get them through the several months during which they fast. Hibernation typically lasts 3–8 months, depending on regional climate. Hibernating bears spend their time in hollowed-out dens in tree cavities, under logs or rocks, in banks, caves, or culverts, and in shallow depressions. Although naturally-made dens are occasionally used, most dens are dug out by the bear. During their time in hibernation, an American black bear's heart rate drops from 40 to 50 beats per minute to 8 beats per minute, and the metabolic rate can drop to a quarter of the bear's (non-hibernating) basal metabolic rate.
== History == Protein C's anticoagulant role in the human body was first noted by Seegers et al. in 1960, who gave protein C its original name, autoprothrombin II-a. Protein C was first isolated by Johan Stenflo from bovine plasma in 1976, and Stenflo determined it to be a vitamin K-dependent protein. He named it protein C because it was the third protein ("peak C") that eluted from a DEAE-Sepharose ion-exchange chromotograph. Seegers was, at the time, searching for vitamin K-dependent coagulation factors undetected by clotting assays, which measure global clotting function. Soon after this, Seegers recognised Stenflo's discovery was identical with his own. Activated protein C was discovered later that year, and in 1977 it was first recognised that APC inactivates Factor Va. In 1980, Vehar and Davie discovered that APC also inactivates Factor VIIIa, and soon after, Protein S was recognised as a cofactor by Walker. In 1982, a family study by Griffin et al. first associated protein C deficiency with symptoms of venous thrombosis. Homozygous protein C deficiency and the consequent serious health effects were described in 1984 by several scientists. cDNA cloning of protein C was first performed in 1984 by Beckmann et al. which produced a map of the gene responsible for producing protein C in the liver. In 1987 a seminal experiment was performed (Taylor et al.) whereby it was demonstrated that activated protein C prevented coagulopathy and death in baboons infused with lethal concentrations of E. coli. In 1993, a heritable resistance to APC was detected by Dahlbäck et al.
Sources: en.wikipedia.org
The ideal relationship between products and reactants in a chemical reaction can be obtained by using a chemical reaction equation. Stoichiometry is used to run calculations about chemical reactions, for example, the stoichiometric mole ratio between reactants and products. The stoichiometry of a chemical reaction is based on chemical formulas and equations that provide the quantitative relation between the number of moles of various products and reactants, including yields. Stoichiometric equations are used to determine the limiting reagent or reactant—the reactant that is completely consumed in a reaction. The limiting reagent determines the theoretical yield—the relative quantity of moles of reactants and the product formed in a chemical reaction. Other reactants are said to be present in excess. The actual yield—the quantity physically obtained from a chemical reaction conducted in a laboratory—is often less than the theoretical yield. The theoretical yield is what would be obtained if all of the limiting reagent reacted to give the product in question. A more accurate yield is measured based on how much product was actually produced versus how much could be produced. The ratio of the theoretical yield and the actual yield results in a percent yield. When more than one reactant participates in a reaction, the yield is usually calculated based on the amount of the limiting reactant, whose amount is less than stoichiometrically equivalent (or just equivalent) to the amounts of all other reactants present.
Alexander Stewart; Joseph Chi-Fung Ng; Gillian Wallis; Vasiliki Tsioligka; Franca Fraternali; Deborah K Dunn-Walters (18 March 2021). "Single-Cell Transcriptomic Analyses Define Distinct Peripheral B Cell Subsets and Discrete Development Pathways". Frontiers in Immunology. 12 602539. doi:10.3389/FIMMU.2021.602539. ISSN 1664-3224. PMC 8012727. PMID 33815362. Alexander Stewart; Emma Sinclair; Joseph Chi-Fung Ng; et al. (3 May 2022). "Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus". Frontiers in Immunology. 13 807104. doi:10.3389/FIMMU.2022.807104. ISSN 1664-3224. PMC 9111746. PMID 35592326. Kate L Gibson; Yu-Chang Wu; Yvonne Barnett; et al. (5 November 2008). "B-cell diversity decreases in old age and is correlated with poor health status". Aging Cell. 8 (1): 18–25. doi:10.1111/J.1474-9726.2008.00443.X. ISSN 1474-9718. PMC 2667647. PMID 18986373. Yu-Chang Wu; David Kipling; Hui Sun Leong; Victoria Martin; Alexander A Ademokun; Deborah K Dunn-Walters (10 May 2010). "High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations". Blood. 116 (7): 1070–1078. doi:10.1182/BLOOD-2010-03-275859. ISSN 0006-4971. PMC 2938129. PMID 20457872. D. K. Dunn-Walters; P. G. Isaacson; J. Spencer (1 August 1995). "Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells" (PDF).
Cry of Fear is a 2013 indie survival horror video game developed and published by the Swedish game development studio Team Psykskallar. It is derived from a mod for the video game Half-Life developed by the same team a year prior. Cry of Fear follows the story of Simon Henriksson, a 19-year-old Swedish male suffering from depression and anxiety, exploring the city of Stockholm. Combining elements of survival horror and first-person shooter mechanics, Cry of Fear challenges players to navigate through a haunting urban environment filled with monsters and unsettling occurrences. The story explores themes of mental illness and trauma. The game was praised for its atmospheric tension, narrative, and innovative use of the Half-Life engine. Cry of Fear received the Mod DB awards for Best Single Player Game of the Year and the Community Award.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.